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Abstract
Diabetes mellitus has long been linked to an increased risk of sudden cardiac death. However,
the magnitude of this association, and the mechanism accounting for this phenomenon, have
not been precisely defined. In this review, we evaluate the epidemiological data pertaining to
the association between diabetes mellitus and sudden cardiac death and discuss various
proposed mechanisms that may account for this relationship. Potential factors contributing to
the increased risk of sudden cardiac death observed in patients with diabetes mellitus include
silent myocardial ischemia, autonomic nervous system dysfunction, abnormal cardiac
repolarization, hypoglycemia, a hypercoaguable state secondary to diabetes mellitus, diabetic
cardiomyopathy, and impaired respiratory response to hypoxia and hypercapnea.
We conclude that diabetes mellitus does appear to be associated with an increased risk of
sudden cardiac death. Although this increased risk is relatively modest, given the large number
of diabetic patients worldwide, the absolute number of sudden cardiac deaths attributable to
diabetes mellitus remains significant. Little evidence exists to support any specific mechanism(s)
accounting for this association. Further investigation into the pathophysiology of sudden car-
diac death in diabetes mellitus may yield improved risk stratification tools as well as identify
novel therapeutic targets. (Cardiol J 2010; 17, 2: 117–129)
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Introduction
Diabetes mellitus (DM) affects an estimated
171 million people worldwide (2000 estimate),
a number projected to double to 366 million by 2030
[1]. Compared to their non-diabetic counterparts,
this substantial portion of the world’s population
appears to be at a significantly higher risk of sud-
den cardiac death (SCD) [2–9]. Recent longitudinal
data from the Framingham cohort and their off-
-spring demonstrates that approximately one-fifth of
sudden deaths occur in the setting of DM, a pro-
portion that has doubled over the past five decades
[10]. Given the recent estimate of up to 400,000
SCDs each year in the United States [11], this would
suggest approximately 80,000 sudden deaths occur
each year in diabetic patients in the United States
alone. While this represents a large number of
SCDs, it is only a very small fraction of the DM
population (< 0.05%).
Despite several epidemiological findings link-
ing DM to SCD, the physiological mechanism(s) re-
sponsible for the increased frequency of sudden
death in diabetic patients has yet to be elucidated.
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This article reviews the epidemiological data
regarding the association between DM and SCD, as
well as exploring the proposed mechanisms behind
SCD in people with DM.
The study of sudden cardiac death
It is important to briefly review some of the
complicating factors that have made the study and
characterization of SCD so challenging to date.
Firstly, the lack of a single, accepted definition of
SCD has made data comparison between studies,
as well as generalizations based on available stud-
ies, quite difficult. SCD has typically been defined
as unexpected death occurring within a specific
period of time after the onset of initial symptoms.
The time frame used to define SCD has varied sig-
nificantly among studies, ranging from less than one
hour after symptom onset up to 24 hours [12] (WHO
definition). The impact that the time frame chosen
can have on the etiology of sudden death is illus-
trated in an older study of 3,421 natural deaths.
Twelve percent of natural deaths were sudden
when ‘sudden death’ was defined as < 2 hours from
the onset of symptoms, and 88% of these were from
a cardiac etiology. In contrast, 32% of natural deaths
were ‘sudden’, and only 75% were from a cardiac
etiology, when the definition was extended to death
within 24 hours of symptom onset [13].
Another factor that introduces variability into
the study of SCD is the variety of methods used for
confirming cases of SCD. These range from rely-
ing solely on information found on death certificates
to more complex assessments, including combina-
tions of autopsy report review, eyewitness inter-
views, and expert panel discussions. Chugh et al.
[14] compared a prospective, comprehensive ap-
proach for the identification of SCD (including anal-
ysis of circumstances of death, medical records, and
available autopsy data) to a retrospective surveillance
approach using only death certificate information in
a population of 660,486 people. Interestingly, the ret-
rospective death certificate-based review had a pos-
itive predictive value of only 19% when compared
to the prospective comprehensive approach, demon-
strating the sizeable effect that the method used to
identify cases of SCD has on study results.
Diabetes and sudden cardiac death
In the published epidemiological studies per-
taining to the role of DM in SCD, patients with DM
appear to be at a higher risk of SCD. Table 1 [2–9,
15, 16] lists these available studies including study
type, study populations, outcomes measured, and
multivariate adjusted relative risk. Of the seven
studies listed, five are prospective population stud-
ies while the remaining two are of case-control de-
sign. Overall, five of the seven studies (three pro-
spective studies and the two case-control studies)
noted a positive, statistically significant relationship
between DM and SCD, while the two remaining stud-
ies failed to find an association.
On closer examination, several differences can
be identified that could potentially contribute to the
heterogeneity of data. In examining the differences
in study populations, the percentage of study sub-
jects with DM was lowest (of those with data availa-
ble) in the two negative studies. The follow-up du-
ration was also substantially shorter in these two
negative studies compared to the positive prospec-
tive studies. Following more subjects for a longer
time may have increased the ability of the positive
studies to detect a significant effect of DM on SCD
that could not be detected in the shorter, negative
studies that had fewer diabetic participants.
Another difference to consider is that incidence
rates of SCD were substantially higher in the two
negative studies compared to the positive studies.
This was probably partly a result of differences in
the inclusion and exclusion of subjects with known
coronary artery disease. Two of the three prospec-
tive studies with positive results excluded patients
with a history of coronary artery disease (CAD),
while the two studies with negative results both
included subjects with a history of CAD (25% and
32% of total study populations, respectively). It is
possible that the competing risks for SCD related
to CAD and other associated factors in these popu-
lations overweighed the increased risk related to
DM. It is therefore critical to assess the risk for
SCD in the comparator population.
Turning now to how SCD cases were defined
and identified in the studies, Table 2 lists the defi-
nitions of SCD used in each study, along with the
methods used to identify cases of SCD. In the Group
Health Cooperative study, Jouven et al. [6] do not
specifically state a cut-off for defining SCD, but all
other studies use < 1 hour from symptom onset in
their definition. An ‘unwitnessed death’ (a death in
which the specific time intervals from symptom
onset until death could not be determined), was
excluded from the definition of SCD in all studies
except for the Suhonen et al. [16] study. Interest-
ingly, this study also had the highest incidence rate
of SCD. The methods used to identify cases of SCD
are also listed in Table 2 for each study and could
also contribute to the differences among studies.
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Another major factor to consider in examining
each study is the validity of the covariate analysis.
Given that certain traditional risk factors for SCD,
such as CAD, hypercholesterolemia, and hyperten-
sion are also quite common in patients with DM,
this puts a great deal of weight on proper covariate
identification and analysis in determining any inde-
pendent relationship between DM and SCD. Overall,
major covariates related to SCD appear to be taken
into account in all the studies examined (Table 2),
Table 2. Determination of sudden cardiac death (SCD) by study and accounted for covariates.
Author Definition of SCD Method to determine Covariates
etiology of SCD
Jouven et al. ‘a natural death occurring Data: medical records, Age, BMI, tobacco use,
1999 [2]  within 1 hour of onset of primary care physicians, HR, blood pressure,
acute symptoms’ death certificates cholesterol level,
Review: independent review triglyceride level,
board of 3 physicians parental history of MI,
parental history
of sudden death
Balkau et al. As above As above As above
1999 [3]*
Albert et al. ‘death or cardiac arrest Data: death certificates, Age,  BMI, tobacco use,
2003 [4]  that precipitated the medical records, next hypertension,
terminal event occurred of kin interviews hypercholesterolemia,
within 1 hour of Review: cases reviewed parental history of MI,
symptom onset’ by 2 cardiologists prior CAD, menopausal
status, postmenopausal
hormone use
Curb et al. Non-traumatic death Data: abstracted death Age, BMI, tobacco use,
1995 [5]  occurring suddenly or certificates, hospital and blood pressure, cholesterol
unexpectedly < 1 or autopsy records, reports from level, triglycerides,
< 24 hours after the onset family, attending physician, alcohol use, left ventricular
of the terminal episode and or medical examiner hypertrophy
resulting from coronary Review: panel of physicians
heart disease or unknown
cause
Jouven et al.  ‘sudden pulseless condition Data: death records, Age, BMI, tobacco use,
2005 [6] in the absence of evidence medical record, HR, systolic blood
of a non-cardiac condition as pharmacy record pressure, cholesterol level,
the causes of cardiac arrest’ history of MI, antidiabetic
treatment, CHF, creatinine
Sexton et al. ‘SCD occurring in a person Data: death records, Age, BMI, tobacco use,
1997 [9] without any prior overt necropsy reports, hospital hypertension,
manifestations of ischemic records, questionnaires  hypercholesterolemia,
 heart disease, where a SCD completed by the subjects family history of CAD,
is one that occurs within doctor, family member exercise amount,
1 hour of the onset of symptoms interviews alcohol use
of myocardial ischemia’
Wannamethee ‘an event in which death Data: inquiry forms for Age, HR, systolic blood
et al. 1995 [15] occurred within 1 hour after the doctor that certified pressure, cholesterol
the onset of symptoms’ the death  level, CHD, arrhythmia,
patients found dead in  physical activity, hematocrit,
bed were not classified and white blood cell count
as SCD
Suhonen  ‘coronary deaths Data: death certificates, Age, BMI, tobacco use,
et al. 1998 [16] ensuing within 1 hour hospital and necropsy blood pressure, cholesterol
of the onset of symptoms records, information level, CHD
or unwitnessed were from witnesses
classified as sudden’
*Used the same study population as Jouven et al. 1999 (Paris Prospective Study); BMI — body mass index; CAD — coronary artery disease;
CHF — congestive heart failure; MI — myocardial infarction; HR — heart rate; CHD — coronary heart disease
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although the development of CAD and its identifica-
tion during the studies’ follow-up periods is not spe-
cifically addressed in many of the studies.
Despite these issues, the data lends overall
support to the existence of a relationship between
DM and SCD. However, further studies of larger,
more diverse populations are needed to solidify the
nature and scope of this relationship.
Mechanisms of sudden cardiac death
Although many mechanisms have been pro-
posed to explain the increased risk of sudden death
in patients with diabetes, little definitive clinical
evidence exists to support any one in particular.
Overall, it is important to remember that SCD is
a complex, heterogeneous entity with several dif-
ferent pathophysiological processes manifesting in
the same final outcome (SCD). It is also important
to realize that chronic factors, as well as acute fac-
tors, play a role in the overall pathogenesis of SCD
in most cases. For instance, chronic factors such as
structural heart disease or underlying coronary
heart disease may make individuals more suscep-
tible to SCD by lowering their threshold for lethal
arrhythmia; but an acute event is also usually need-
ed such as an acute plaque rupture, an electrolyte
imbalance, or a surge of sympathetic activity, in
order to trigger the fatal event. It is this heteroge-
neity and level of complexity that has made the
characterization of SCD etiologies and risk factors
so difficult in the past.
Before discussing mechanisms of SCD in the
diabetic population, it is important to first briefly
review causes of SCD in the general population.
Although difficult to study, arrhythmia has been
reported as the mechanism of sudden death in ap-
proximately 90% of sudden cardiac deaths [4, 17].
Hinkle and Thaler [17] used the definition of ‘an
abrupt collapse with pulse ceasing prior to circula-
tory collapse’ to define arrhythmic death in their
study of 142 deaths; they found that 58 (41%) of
these deaths occurred within one hour of the ter-
minal illness. Of these 58 deaths, 53 (91%) were
classified as ‘arrhythmic deaths’.
Albert et al. [4] examined 570 sudden deaths
in women and found that 88% were arrhythmic us-
ing this same definition. Other etiologies, such as
acute heart failure from massive myocardial infarc-
tion, occur far less frequently. In another study,
SCD was classified further into three categories in
a sample of 106 SCDs. In this study, 47% of SCDs
were arrhythmic (without evidence of ischemia),
43% were ischemic (i.e. with any evidence of
ischemia or infarction) and 8% were secondary to
myocardial pump failure [18].
Coronary artery disease is thought to play
a major role in SCD in the general population and
is present in approximately 80% of cases of SCD in
Western countries, while non-ischemic cardiomyo-
pathies make up only 10–15% of SCD cases. Vari-
ous autopsy studies have shown that between 55%
and 86% of patients who experience SCD have sig-
nificant (> 75%) stenosis of at least two coronary
arteries [19–21]. While underlying chronic CAD
appears to be common in SCD, the frequency of
finding acute coronary thrombosis in cases of SCD
is far less clear. In a compilation of studies report-
ed by Farb et al. [19], acute coronary thrombi were
found in 5–73% of SCD autopsy cases, depending
on the cohorts studied and definition of SCD used.
Thus, while chronic coronary disease appears to
play a significant role in SCD, the acute inciting
events that precipitate SCD are less clear. Other
major risk factors that have been established for
SCD include decreased left ventricular ejection frac-
tion, intraventricular conduction delay, autonomic
nervous system abnormalities, risk factors associ-
ated with the development of coronary artery dis-
ease, left ventricular hypertrophy, history of prior
cardiac arrhythmia, clinical congestive heart failure,
and family history of SCD.
Mechanisms of sudden death in
diabetes mellitus
Within the diabetic population, several mech-
anisms have been proposed to account for the ex-
cess of SCD observed. These mechanisms include
silent myocardial ischemia, autonomic dysfunction,
QT interval prolongation, hypoglycemia, a hyper-
coaguable state associated with DM, diabetic car-
diomyopathy, and decreased ventilatory response
to hypoxia and hypercapnea.
Silent ischemia
Several authors have suggested that silent,
unrecognized ischemia eventually leads to lethal
arrhythmias and SCD in diabetic patients. To date,
the DIAD (Detection of Ischemia in Asymptomatic
Diabetics) trial is the only prospective trial to eval-
uate the prevalence of silent myocardial ischemia
in a large group of diabetic subjects. In this trial,
522 asymptomatic type 2 diabetic subjects (average
age 60.7 years) without a history of coronary artery
disease underwent stress testing by single photon
emission-computed tomography (SPECT) imaging,
with 15.9% of subjects demonstrating abnormal
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myocardial perfusion [22]. This is a significantly
smaller percentage compared to two large retro-
spective studies of 826 [23] and 1,427 [24] subjects
which found abnormal SPECT imaging in 39% [23]
and 58% [24] of asymptomatic diabetic patients, re-
spectively.
Of the available studies, the reported preva-
lence of ‘silent’ ischemia ranges from 6–59% [22–
–28] in subjects with diabetes. Of note, no large
scale prospective study has reported the results of
angiographic evaluation following positive imaging
studies in these asymptomatic diabetics. In addition,
many of these studies do not report rates of ‘silent
ischemia’ in non-diabetic control subjects, although
2.5–15% [29, 30] of non-diabetic patients have been
reported to have ‘silent ischemia’ in other studies.
Little is known regarding the prognostic impli-
cations of ‘silent ischemia’ in DM. In one study of
1,737 diabetic patients consecutively referred for
cardiac stress testing, asymptomatic subjects with
abnormal myocardial perfusion testing were found
to have an annual event rate (events defined as myo-
cardial infarction or cardiac death) of 3.4%, versus
an event rate of 1.6% in asymptomatic subjects with
normal myocardial perfusion scans (p = 0.009) [23].
Another non-randomized trial demonstrated
that asymptomatic diabetic patients with high risk
SPECT imaging had a survival benefit at five years
from coronary artery bypass graft surgery (85%
survival) or percutaneous coronary intervention
(72%) versus medical therapy alone (67%) [31].
There are no studies that report on the attrib-
utable risk of SCD due to silent ischemia in diabet-
ic patients. In the absence of screening for silent
ischemia in SCD studies, the higher rate of unrec-
ognized CAD in diabetic subjects would not be tak-
en into account in multivariable analysis models.
Therefore the additional risk of SCD afforded by this
unrecognized CAD may instead be attributed to
diabetes itself. Further studies of the impact of si-
lent ischemia on the risk of SCD are needed. In
addition, screening for silent ischemia should ide-
ally be performed at the onset of all studies pertain-
ing to DM and SCD to ensure that all known SCD
risk factors are completely accounted for in multi-
variable analysis.
Autonomic dysfunction
An imbalance in autonomic tone has been
linked to an increased risk of sudden death and/or
susceptibility to ventricular arrhythmias in
a number of different settings in diabetic and non-
-diabetic populations. For example, animal studies
have demonstrated that sympathetic stimulation
causes an increased incidence of reperfusion-in-
duced ventricular fibrillation in dogs [32]; and con-
versely that parasympathetic stimulation decreas-
es the incidence of ventricular fibrillation during
ischemia in exercising dogs [33].
Changes in autonomic tone are frequently seen
in diabetic patients and have been studied using
a number of different methods. Diabetic cardiac au-
tonomic neuropathy (CAN) has been assessed us-
ing a number of tests, including: measurements of
heart rate and blood pressure response to specific
maneuvers (standing up, sustained handgrip, and
Valsalva) [34] and various measures of heart rate
variability. The prevalence of CAN varies widely de-
pending on the cohort studied and the tests and
criteria used for its assessment, but ~15–20% of
asymptomatic individuals with diabetes appear to
have abnormal cardiovascular autonomic function
[35–38]. Earlier studies on CAN supported the
premise that parasympathetic dysfunction (dimi-
nished heart rate variability) precedes sympathetic
dysfunction (such as orthostatic hypotension) in
the natural course of the disease [39, 40]. Howev-
er, some have argued that the higher sensitivities
of tests that assess parasympathetic function com-
pared to tests of sympathetic function could ac-
count for the earlier detection of parasympathetic
abnormalities [41]. In fact, Schnell et al. [42] de-
scribe the detection of sympathetic denervation in
subjects with type 2 DM and no evidence of CAN
(assessed through five cardiac reflex tests) using
I-123-metaiodobenzylguanideine (I-123-MIBG)
scintigraphy.
Both patient age and duration of DM appear to
be significant risk factors for the development of
CAN in both type 1 and type 2 DM [43–47], although
CAN has been found in both children and adults at
initial diagnosis of DM. In a study of 3,250 subjects
with type 1 DM followed prospectively over a ten
year period, age was associated with an increased
risk of developing CAN with an odds ratio of 1.3 per
decade (95% CI 1.1–1.7) in a multivariate regres-
sion model [47]. In a study of 325 type 1 DM pa-
tients, duration of DM was found to be an independ-
ent predictor for the development of CAN at two
year follow-up based on Cox proportional hazards
modeling (Coeff/S.E. = 4.48, p = 0.0000) [43].
Within the diabetic population, the presence of
autonomic nervous system dysfunction appears to
impart a higher mortality risk [43, 48–61]. In a meta-
analysis of 15 studies among individuals with DM,
CAN was found to be consistently and significantly
associated with subsequent mortality [43, 51, 54,
59–61]. The pooled relative risk for studies that
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defined CAN by the presence of two or more ab-
normal cardiac reflex tests was 3.45 (95% CI 2.66–
–4.47; p < 0.001) [51]. In addition to an increase in
all-cause mortality risk, diabetic patients with CAN
have an increased risk of major cardiovascular
events [56, 62] and post-myocardial infarction mor-
tality [63, 64] as well.
An increased frequency of sudden cardiac death
among subjects with CAN has been reported in
a number of studies  [49, 54, 59, 65, 66]. While early
small observational studies suggested that CAN
was independently associated with an increased risk
of sudden cardiac death [49, 54, 59, 65], a more re-
cent, larger prospective study [66] has questioned
the strength of this association. In this recent study
by Suarez et al. [66], 462 patients with DM were
followed over 15 years, with 21 cases of SCD re-
ported over this period. Subjects with CAN were
found to have a hazard ratio of 1.52 (1.2–1.91) for
SCD on univariate analysis, although this was not
significant after multivariate analysis. Review of
medical records and necropsy reports of the cases
of SCD showed that all subjects had either severe
coronary atherosclerosis with myocardial damage
at necropsy or a clinical history of atherosclerosis
with left ventricular dysfunction. This led the
authors of the study to postulate that underlying
coronary atherosclerosis, myocardial injury and
kidney disease alone appeared to be sufficient to
account for sudden cardiac death in these patients,
with CAN probably playing a lesser role.
Several factors may account for the discrepan-
cies among these studies. Firstly, the relatively
small sample sizes of these studies, particularly the
earlier ones, brings into question the  general ap-
plicability of the data obtained from each. Another
major difference is the various methods used to de-
fine CAN. Measurements and scoring for CAN in
the studies differ significantly in terms of both the
tests used and the overall numeric scoring systems
and thresholds applied. For instance, the ‘sudomo-
tor’ component that makes up approximately one
third of the CASS score used by Suarez et al. [66]
to assess for CAN is not present in systems used
by the other studies. It should be noted that this
sudomotor portion of the CASS score had the least
degree of association with SCD on multivariate ana-
lysis (0.66; 95% CI 0.27–1.60), with the other two
portions of the CASS score both showing adjusted
hazard ratios trending towards an association with
SCD (adrenergic 1.27; 95% CI 0.65–2.47) and car-
diovagal 1.49 (95% CI 0.82–2.72). Overall, the data
on the association between CAN and SCD is very
limited and appears insufficient to make a reliable
conclusion regarding the relationship between
these two entities at this time.
QT interval prolongation
QT interval prolongation reflects changes in
ventricular repolarization and predicts mortality in
many populations. A prolonged QT interval (QTc
> 440 ms) on the surface electrocardiogram (ECG)
is an independent predictor of increased mortality
in patients with ischemic heart disease and heart
failure [67–69] as well as in apparently healthy sub-
jects [70]. An increased incidence of SCD associat-
ed with QTc prolongation has also been described
in a number of studies [67, 70]. The Rotterdam QT
Project examined 6,693 consecutive patients under-
going 24 hour ECG monitoring and found that after
a two year follow-up, QTc > 440 ms resulted in
a RR of 2.1 (95% CI 1.4–3.1) for SCD compared to
patients with a QTc < 440 ms [67].
Prolongation of the QT interval is common in
DM [71–74]. In a study of 379 type 1 DM patients
and 118 non-diabetic control subjects, the QTc inter-
val was greater than 440 ms in 7.6% of control sub-
jects, 25.6% of diabetic patients, and 30.8% of those
with diabetic autonomic neuropathy [71]. Similarly, in
a cohort of 1,357 patients with type 2 DM, the preva-
lence of QTc prolongation was found to be 25.8% [74].
The poor prognostic significance of QTc pro-
longation is present in DM patients as well [55, 57,
75–80]. In several recent studies, QTc interval pro-
longation was found to be a significant risk factor
for all-cause and cardiac mortality in type 1 DM
patients. Even after adjustment for other estab-
lished risk factors for excess mortality in diabetic
patients (e.g. age, duration of disease, blood pres-
sure, ischemic heart disease, and smoking), QT
interval prolongation remained a significant, inde-
pendent and powerful predictor of mortality. For
example, in a study of 316 type 1 DM patients with
an overall mortality of 6.23% at five years, prolonged
QTc (> 440 ms) was the only variable associated
with increased mortality in multivariate analysis with
an odds ratio of 24.6 (95% CI 6.51–92.85) [57].
A prospective study of 182 subjects with new-
ly diagnosed type 2 DM without apparent compli-
cations at baseline and followed up for a mean of
10.3 years, showed a significant (p < 0.001) rela-
tionship between cardiac death and maximum QTc
interval at baseline visit. Additionally, maximum
QTc and QT dispersion were both highly significant
and independent predictors of cardiac death at three
year and six year visits [75]. In the Strong Heart
Study of 994 American Indians with type 2 DM followed
over a mean of 4.7 years, QTc interval > 460 ms
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demonstrated a hazard ratio of 2.03 (95% CI
1.32–3.12) for all-cause mortality [81]. In another
prospective study of 697 patients with type 1 DM
(mean age 41 years) followed for ten years, QTc
prolongation was an independent predictor of mor-
tality. Mortality was 29% in those with prolonged
QT intervals, compared to 19% in those with nor-
mal QTc (p < 0.001) [76].
Prolongation of baseline QTc interval has also
been suggested as increasing the risk of SCD in
the diabetic patient, although little data exist to con-
firm this association. A single case control study
consisting of 79 cases of SCD and 214 controls with
type 2 DM and no known coronary heart disease,
found a 3.5 (1.6–7.6)-fold higher risk of SCD for
subjects with baseline QT interval lengths in the
fourth quartile (longest) compared to subjects in the
first quartile of baseline QT interval length (short-
est) after adjustment for age and race [80]. Obvi-
ously, more studies are needed regarding this as-
sociation before generalizations can be made re-
garding QTc as a significant risk factor for SCD in
the diabetic population.
Association between cardiac
autonomic neuropathy and QT interval
Interestingly, a strong association exists be-
tween CAN and QT interval prolongation. The QT
interval has even been proposed as a screening tool
to identify diabetic patients with CAN. Multiple
studies have found a linear relationship between the
severity of CAN and the degree of QTc prolonga-
tion in diabetic patients. For instance, in one study
of 100 diabetic patients, the coefficient of correla-
tion between CAN score (0–3) and QTc interval was
0.73 (p < 0.001) [82]. In a smaller study of 30 pa-
tients with type 1 DM, a similar coefficient of cor-
relation was found between CAN score (0–5) and
QTc interval both at rest (r = 0.718, p < 0.001) and
with exercise (r = 0.719, p < 0.001) [83]. While
a number of identified factors, such as age and coro-
nary artery disease, have been associated with pro-
longation of QTc intervals, a specific autonomic
contribution to QTc prolongation in patients with
CAN has been suggested. One retrospective study
examined QT/RR interval relationships from
24 hour ECG recordings performed initially and then
repeated several years later (average three years,
range 2–6 years) for three groups of patients (con-
trol subjects [n = 13], diabetic subjects without
CAN [n = 13], and diabetic subjects with CAN
[n = 13]) [65]. Significant changes in the QT/RR rela-
tionship (longer QT for any given RR) were found
to be associated only with changes in autonomic
function testing and were not significantly correlat-
ed with age or length of time between recordings.
Although the exact mechanism behind increased
QT interval duration in CAN has yet to be elucidat-
ed, imaging studies using radiotracers (MIBG) to
evaluate myocardial sympathetic innervation have
demonstrated intracardiac sympathetic imbalance
in patients with CAN [84–87] suggesting that this
may be a potential contributing factor to QT pro-
longation. This relationship offers yet another
mechanism by which autonomic dysfunction in DM
may contribute to SCD through the induction of
abnormalities of ventricular repolarization, which in
turn may lead to ventricular tachyarrhythmias.
Hypoglycemia
Experimentally induced hypoglycemia has
been shown to cause changes in ventricular repo-
larization in a few small studies [88–90]. In one
study of 15 subjects with DM (seven with type 1
DM, eight with type 2 DM), significant changes in
QTc were found after controlled hypoglycemia was
maintained using hyperinsulinemic glucose clamps.
In patients with type 1 DM, QTc increased from
421 ms (362–436 ms) at baseline to 583 ms (421–
–633 ms) after 120 minutes of hypoglycemia (glu-
cose level of approximately 55 mg/dL; p < 0.01)
[88]. A similar trend was demonstrated when pa-
tients with type 2 DM underwent the same study.
In a follow-up study, beta-blockade was found to
nearly abolish the effects of hypoglycemia on QTc
prolongation, while potassium infusion did not have
a significant effect on QTc during hypoglycemia
[90]. This, along with data showing increases in cat-
echolamines associated with hypoglycemia, sup-
ports the theory that QTc prolongation is driven by
sympathoexcitation during hypoglycemia.
Dead in bed syndrome, a term used to describe
the phenomenon of unexpected death in young (< 50)
type 1 diabetics while sleeping, was first described by
Tattersall and Gill [91] in 1991 through a review of
22 cases of sudden death in otherwise healthy young
type 1 diabetic patients with no significant structur-
al heart disease found on autopsy. Subjects were of-
ten found with their beds undisturbed (no signs of
struggle, seizure or sweating), leading many to hy-
pothesize that death was secondary to sudden lethal
arrhythmia. Given the fact that these deaths occurred
at night, and the fact that the nadir of glucose levels
typically occurs at night during sleep, many have also
implicated hypoglycemia as a contributing mecha-
nism to death in these cases.
Unfortunately, given the difficulty in identify-
ing hypoglycemia by post-mortem examination, the
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etiology behind this phenomenon remains, for the
most part, theoretical. A recent study by Gill et al.
[92] used continuous glucose monitoring and
24 hour ECG recordings in 25 type 1 diabetic pa-
tients (ages 20–50 years) to monitor for hypoglyc-
emia and any related rhythm disturbances. Thirteen
episodes of nocturnal hypoglycemia were identified
in the study, with eight cardiac rate and rhythm dis-
turbances noted during these periods. These elec-
trocardiographic disturbances included sinus brady-
cardia with heart rate <40 bpm (3), ventricular ec-
topic beats (3), atrial ectopic beats (1) and P wave
abnormalities (1). Notably, these abnormalities
were not observed when monitoring during normo-
glycemia. Some have hypothesized that baseline
QTc prolongation from CAN, transient QTc prolon-
gation from hypoglycemia, and an underlying genet-
ic predisposition all combine to induce a lethal ar-
rhythmic event in cases of dead in bed syndrome
[93]. Interestingly, in a single study of 28 type 1
diabetic subjects and eight control subjects, subjects
with CAN tended to show smaller increases in QTc
with hypoglycemia compared to diabetic subjects
without CAN and non-diabetic controls [94].
The ACCORD trial noted increased mortality
in patients with type 2 DM randomized to intensive
glucose lowering compared to standard therapy
[95]. This group also experienced increased hypogly-
cemic episodes. Although an increased incidence of
fatal arrhythmias was not documented in the inten-
sive glucose lowering group, it is possible that there
is a link between hypoglycemic episodes and SCD.
Hypercoaguable state
Other authors have suggested that a hyperco-
aguable state exists in patients with DM and leads
to a higher incidence of catastrophic coronary
thrombosis after plaque rupture, thus resulting in
a higher rate of sudden fatal coronary events. In-
deed, expression of glycoprotein IB and IIB/IIIA
have been shown to be increased in DM [96], which
in theory augments the interaction of platelets with
both von Willebrand factor and fibrin.
In addition, plasma coagulation factors such as
factor VII, thrombin and other procoagulants such
as tissue factor have been shown to be increased in
DM [97–99]. Plasminogen activator inhibitor-1
(PAI-1) which inhibits fibrinolysis has also been
shown to be increased in patients with type 2 DM
[100, 101]. In theory, all these factors could lead to
increased thrombosis following plaque rupture, al-
though outcomes studies, correlating coagulation
measures in patients with diabetes with subsequent
SCD outcomes, have not been performed.
Diabetic cardiomyopathy
Diabetic cardiomyopathy is the term used to
describe the effects of diabetes on cardiac structure
and function in the absence of coronary artery dis-
ease or hypertension. Data from the Framingham
cohort has demonstrated increased rates of heart
failure in diabetic subjects even after adjustment for
coronary artery disease, hypertension, hypercho-
lesterolemia and obesity [102]. Several possible
mechanisms have been identified, including inter-
stitial fibrosis [103], glycation of collagen leading
to impaired contractility [104, 105], changes in cal-
cium homeostasis [106], and autonomic dysfunc-
tion. In addition to systolic dysfunction, diastolic
dysfunction has also been found to be common in
diabetic patients, with a prevalence as high as
30–60% reported in some studies [107, 108].
Given that systolic dysfunction increases the
risk of SCD in the general population and that the
effect of diastolic dysfunction on SCD is relatively
unknown, some have proposed that diabetic cardio-
myopathy may account for the increased rates of
SCD in diabetic patients. While most studies exam-
ining the association between SCD and DM have
excluded patients with clinical congestive heart fail-
ure, the incidence of clinically unrecognized systo-
lic dysfunction in people with diabetes is unknown.
Further studies on the characterization of diabetic
cardiomyopathy as well as outcomes associated
with it are needed.
Impaired respiratory response
Some authors have proposed that a decrease
in ventilatory response to hypoxia and hypercapnea
contributes to increased SCD in patients with dia-
betes, particularly those with CAN. Several small
studies have demonstrated a decreased response
to hypoxia [109–111] in diabetic cohorts, with this
deficit being most pronounced in diabetic subjects
with CAN. Other studies have failed to find a dif-
ference [112, 113]. The response to hypercapnea
in subjects with diabetes has varied, with studies
showing increased [114], unchanged [112] and de-
creased ventilatory rates [111, 114] in response to
experimentally induced hypercapnea in various
diabetic cohorts. Interestingly, Tantucci et al. [114]
found a blunted response to hypercapnea in diabet-
ic subjects without CAN, and in diabetic subjects
with CAN and only parasympathetic dysfunction. In
contrast, diabetic subjects with evidence of CAN
with both parasympathetic and sympathetic dys-
function had an increased response to hypercapnea
compared to controls. Unfortunately, no significant
outcome data have been published to establish an
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association between ventilatory changes associat-
ed with DM and the risk of SCD.
Summary and future directions
In summary, it appears plausible that DM is
associated with an increased risk of SCD. Although
this increased risk appears relatively small, given
the large number of diabetic patients worldwide this
may in fact represent a large number of SCDs and
a substantial percentage of all SCDs (Fig. 1).
Multiple pathophysiological changes associat-
ed with DM have the potential to increase the risk
of SCD. However, at this time there are insufficient
data to define the contributions that any of these
changes have on the risk of SCD in patients with
diabetes.
Future studies on SCD and DM are needed to
solidify the relationship between these two entities.
These studies should focus on identifying and account-
ing for covariates that are known risk factors for SCD
but may be unrecognized in patients with DM (i.e.
silent CAD or undiagnosed structural heart disease).
In order to unravel the mechanism(s) behind
the increased risk of SCD in DM, further investi-
gation is needed. Rates and degrees of acute and
chronic coronary artery disease and myocardial
damage have yet to be adequately defined in dia-
betic patients with SCD and need to be compared
with cases of SCD in non-diabetic patients. Varia-
bles such as cardiac autonomic tone, ventilatory
control, coagulation factor levels, diastolic ventricu-
lar function, hypoglycemia frequency/awareness,
and the presence or absence of symptoms with
myocardial ischemia have yet to be adequately as-
sessed for their associations with SCD.
Defining a unique or preferentially more com-
mon mechanism behind SCD in the diabetic patient
offers an exciting opportunity for new and improved
SCD risk stratification methods that are specifical-
ly tailored to the diabetic patient. It may also lend
further insight into the risks and benefits of com-
monly prescribed treatments such as beta-blockers,
anticoagulants, aggressive glycemic control, and
exercise programs in patients with DM.
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